Celebrating a Decade of
Clinical Excellence

Dr. Farbod Rastegar Now Offers Improved Treatment for Cervical Disc DIsease

Successful Surgery with Mobi-C Cervical Disc at Two Levels Allows Patient to Maintain Neck Motion

Mobi-C® Cervical Disc replaces diseased discs in the neck and is designed to maintain motion similar to the natural cervical spine. Traditionally, the same patient would have received a fusion. Fusion surgery, while also replacing diseased discs in the neck, is designed to stop movement at the operated levels. Often times when you fuse, stress can be transferred to the adjacent discs, which can result in additional surgeries or accelerated disc degeneration.[1]

Mobi-C received FDA approval in 2013, making it the first cervical disc in the U.S. approved to treat more than one level of the cervical spine. Upon approval, Mobi-C was non-inferior to fusion at one level and SUPERIOR to fusion at two levels.

In 2018 the FDA approved the 7 year clinical results, confirming that Mobi-C at two levels continued to demonstrate ***superiority*** over fusion based on overall study success. Those patients who received two level cervical disc replacement during the trial returned to work on average approximately three weeks earlier as compared to the fusion patients.

Upon completion of the 7-year FDA IDE study, follow-up continued on a subset of Mobi-C patients with the goal of obtaining 10-year follow-up on all eligible patients. At 10 years, all patient-reported outcomes of Mobi-C recipients were equivalent to or improved from 7 years. Recipients of Mobi-C reported improved Neck Disability Index (NDI) Scores, improved neck pain, and improved arm pain. In addition, no subsequent surgery at an adjacent level occurred between the 7 year and 10 year follow up.[1,2]

In 2023, ZimVie announced that over 200,000 Mobi-C Cervical Discs have been implanted globally. This milestone aligns with the ten-year anniversary of Mobi-C FDA approval for treatment of one and two levels of the cervical spine.

“I am very happy to be able to offer my patients this state-of-the-art procedure which is supported by the highest level of medical evidence available for a medical device,” said Dr. Farbod Rastegar of Cincinnati Elite Orthopedic and Spine.” With Mobi-C I am able to offer to many of my patients who suffer from two-level cervical disease a superior treatment option to traditional cervical spine fusion that maintains motion.”

About the Mobi-C Cervical Disc
Mobi-C is the first cervical disc prosthesis approved by the FDA for reconstruction of a cervical disc at both one and two levels (C3-C7). Mobi-C is a cobalt chromium alloy and polyethylene mobile-bearing prosthesis that is inserted in a single step, without requiring bone chiseling or other vertebral anchorage such as screws or keels. The Mobi-C Cervical Disc Prosthesis is indicated in skeletally mature patients for reconstruction of the disc from C3-C7 following

discectomy at one level or two contiguous levels for intractable radiculopathy (arm pain and/or neurological deficit) with or without neck pain or myelopathy due to abnormality localized to the level of the disc space and at least one of the following conditions confirmed by radiographic imaging (CT, MRI or X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes) and/or visible loss of disc height compared to adjacent levels. The Mobi-C Cervical Disc Prosthesis is implanted using an anterior approach. Patients should have failed at least six weeks of conservative treatment or demonstrated progressive signs or symptoms despite nonoperative treatment prior to implantation of the Mobi-C Cervical Disc Prosthesis.

Common post-operative risks from surgery with the Mobi-C include pain in the neck, arm, back, shoulder, or head, and dysphagia. For complete indications, contraindications, warnings, and risks on the Mobi-C Cervical Disc or to find more information on other ZimVie Spine solutions, please visit https://www.zimvie.com/en/spine.html.

About

References:

1. Kim K, Hoffman G, Bae H, et al. Ten-Year Outcomes of 1- and 2-Level Cervical Disc Arthroplasty From the Mobi-C Investigational Device Exemption Clinical Trial. Neurosurgery. 2021;88(3):497-505.
2. Radcliff K, Davis RJ, Hisey MS, et al. Long-term evaluation of cervical disc arthroplasty with the Mobi-C Cervical Disc: a randomized, prospective, multicenter clinical trial with seven-year follow-up. Int J Spine Surg 2017;11(4):244-262.